When Key Decisions Can’t Wait For Certainty
Supporting pharma new product planning when evidence is incomplete and recommendations still need to be made
Independent pharma new product planning (NPP) consulting for pipeline, portfolio, and business development decisions
Your Reality:
- Making calls while the evidence is still emerging
- A “yes” to one opportunity is often a “not now” to something else
- Recommendations inform where resources go, which indications remain viable, and which partnering paths stay open
Strategic Decisions:
- Which opportunities to pursue
- Advance, partner, or acquire
- Which programs to keep backing
- What is the evidence threshold
Your Challenge:
- Improving recommendations while there is still time to affect the outcome
- Judging what matters most when options are uneven
- Making assumptions visible
- Standing behind a point of view before the evidence can settle the question
This is the kind of NPP work I support
Opportunity Assessment | Commercial Due Diligence | Portfolio Evaluation | Evidence Strategy | Primary Market Research | Excel-Based Analytical Modeling
If these challenges sound familiar, explore my Project Portfolio page.